MRI Shows Hypothalamic Atrophy in Narcolepsy Type 1, Sparing Subregion
Published: | Updated:
|Articles|October 26, 2012
Pharmaceutical Company to Pay $95M to Settle Allegations of Improper Drug Promotion
Advertisement
Boehringer Ingelheim Pharmaceuticals Inc. will pay $95 million to settle allegations that the company promoted three drugs for uses that were not medically accepted, the government announced Thursday.
The Justice Department said the three are the stroke-prevention drug Aggrenox, the chronic obstructive pulmonary disease drug Combivent and the high-blood-pressure drug Micardis.
Read the full story:
Source: The Washington Post
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Unvaccinated COVID-19 Infection Tied to Higher Myocarditis Risk
2
FDA Expands Tirzepatide Label to Reduce Cardiovascular Risk in Type 2 Diabetes
3
Never-Screened Cervical Cancer Rates Climb Among US Women
4
FDA Approves Brepocitinib as First Oral Drug for Dermatomyositis
5